Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) is now available.
Lepu Biopharma Co., Ltd. successfully held its 2024 Annual General Meeting (AGM) on June 27, 2025, where all proposed resolutions were approved by shareholders. The resolutions included approval of financial reports, profit distribution plans, and the re-appointment of Ernst & Young as auditors, reflecting strong shareholder support and strategic alignment for the company’s future operations.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biopharmaceutical industry. The company is focused on developing and commercializing innovative medicines, with a market focus on addressing unmet medical needs.
Average Trading Volume: 24,415,556
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.58B
Find detailed analytics on 2157 stock on TipRanks’ Stock Analysis page.